Second-line platinum-based chemotherapy after enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: a systematic review
Materials for a systematic review of second-line platinum-based chemotherapy after first-line enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma.
Authors
- Shugo Yajima (ORCID: https://orcid.org/0000-0003-2300-8446)
Publication Details
- Journal
- Open Science Framework
- Published
- 2026-11-17
- DOI
- https://doi.org/10.17605/osf.io/8gc7m
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00